Inhibition of CXCR3-mediated chemotaxis by the human chemokine receptor-like protein CCX-CKR

British Journal of Pharmacology

Volumn 168, Issue 6, 2013, Pages 1375-1387

  Vinet, J ^a,d   Van Zwam, M ^a,e   Dijkstra, I M ^a   Brouwer, N ^a   Van Weering, H R J ^a   Watts, A ^b   Meijer, M ^a   Fokkens, M R ^a   Kannan, V ^a   Verzijl, D ^b   Vischer, H F ^b   Smit, M J ^b   Leurs, R ^b   Biber, K ^c   Boddeke, H W G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chemokine receptors; heteromerization; T cells

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR3; PROTEIN CCX CKR; SCAVENGER; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVITY; CHEMOTAXIS; COMPLEX FORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HETEROMERIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

CELLS, CULTURED; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; DOWN-REGULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; LIGANDS; LUMINESCENT PROTEINS; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RECEPTORS, CCR; RECEPTORS, CXCR3; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 84874440947     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12042     Document Type: Article

References (42)

1. Biber K, Klotz KN, Berger M, Gebicke-Harter PJ, van, Calker D, (1997). Adenosine A1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J Neurosci 17: 4956-4964.
2. Brouwer N, Zuurman MW, Wei T, Ransohoff RM, Bodekke HW, Biber K, (2004). Induction of glial L-CCR mRNA expression in spinal cord and brain in experimental autoimmune encephalomyelitis. Glia 46: 84-94.
3. Catusse J, Leick M, Groch M, Clark DJ, Buchner MV, Zirlik K, et al. (2010). Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia. Mol Cancer 9: 297.
4. Chakera A, Seeber RM, John AE, Eidne KA, Greaves DR, (2008). The duffy antigen/receptor for chemokines exists in an oligomeric form in living cells and functionally antagonizes CCR5 signaling through hetero-oligomerization. Mol Pharmacol 73: 1362-1370.
5. Chomczynski P, Sacchi N, (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
6. Combadiere C, Ahuja SK, Murphy PM, (1995). Cloning, chromosomal localization, and RNA expression of a human beta chemokine receptor-like gene. DNA Cell Biol 14: 673-680.
7. Comerford I, Nibbs RJ, (2005). Post-translational control of chemokines: a role for decoy receptors? Immunol Lett 96: 163-174.
8. Comerford I, Milasta S, Morrow V, Milligan G, Nibbs R, (2006). The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur J Immunol 36: 1904-1916.
9. Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Marullo S, et al. (2008). CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci USA 105: 10101-10106.
10. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, et al. (2001). Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59: 707-715.
11. El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, Parmentier M, (2005). Evidence for negativebinding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 67: 460-469.
12. Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM, (2009). Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 15: 2962-2970.
13. Gosling J, Dairaghi DJ, Wang Y, Hanley M, Talbot D, Miao Z, et al. (2000). Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. J Immunol 164: 2851-2856.
14. Hansell CA, Simpson CV, Nibbs R, (2006). Chemokine sequestration by atypical chemokine receptors. Biochem Soc Trans 34: 1009-1013.
15. Hensbergen PJ, van der Raaij-Helmer EM, Dijkman R, van der, Schors RC, Werner-Felmayer G, Boorsma DM, et al. (2001). Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity. Eur J Biochem 268: 4992-4999.
16. Horuk R, (2001). Chemokine receptors. Cytokine Growth Factor Rev 12: 313-335.
17. Jalink K, Van Rheenen J, (2009). Quantitative imaging of sensitized emission FRET and FLIM techniques. In:, Gadella TWJ, (ed.). Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 33. Academic Press: Burlington, MA, pp. 289-349.
18. Jamieson T, Cook DN, Nibbs RJ, Rot A, Nixon C, McLean P, et al. (2005). The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 6: 403-411.
19. Johnson M, Li AR, Liu J, Fu Z, Zhu L, Miao S, et al. (2007). Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett 17: 3339-3343.
20. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al. (1996). Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 963-969.
21. Martinez de la Torre Y, Locati M, Buracchi C, Dupor J, Cook DN, Bonecchi R, et al. (2005). Increased inflammation in mice deficient for the chemokine decoy receptor D6. Eur J Immunol 35: 1342-1346.
22. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, Fernandez S, Martin de Ana A, Jones DR, et al. (2001). Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J 20: 2497-2507.
23. Murphy PM, (2002). International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature. Pharmacol Rev 54: 227-229.
24. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
25. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, et al. (2005). Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 280: 9895-9903.
26. Rios CD, Jordan BA, Gomes I, Devi LA, (2001). G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 92: 71-87.
27. Rodriguez-Frade JM, Vila-Coro AJ, de, Ana AM, Albar JP, Martinez AC, Mellado M, (1999). The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc Natl Acad Sci USA 96: 3628-3633.
28. Rossi D, Zlotnik A, (2000). The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242.
29. Salanga CR, O'Hayre M, Handel T, (2009). Modulation of chemokine receptor activity through dimerization and cross talk. Cell Mol Life Sci 66: 1307-1386.
30. Sanchez-Madrid F, del Pozo MA, (1999). Leukocyte polarization in cell migration and immune interactions. EMBO J 18: 501-511.
31. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, et al. (2007). Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci USA 104: 14759-14764.
32. Sohy D, Parmentier M, Springael JY, (2007). Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem 282: 30062-30069.
33. Sohy D, Yano H, de, Nadai P, Urizar E, Guillabert A, Javitch JA, et al. (2009). Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of 'selective' antagonists. J Biol Chem 284: 31270-31279.
34. Springael JY, Urizar E, Parmentier M, (2005). Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev 16: 611-623.
35. Springael JY, Le Minh PN, Urizar E, Costagliola S, Vassart G, Parmentier M, (2006). Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol 69: 1652-1661.
36. Thelen M, (2001). Dancing to the tune of chemokines. Nat Immunol 2: 129-134.
37. Thomsen AR, Nansen A, Madsen AN, Bartholdy C, Christensen JP, (2003). Regulation of T cell migration during viral infection: role of adhesion molecules and chemokines. Immunol Lett 85: 119-127.
38. Townson JR, Nibbs RJ, (2002). Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR. Eur J Immunol 32: 1230-1241.
39. Van Rheenen J, Langeslag M, Jalink K, (2004). Correcting confocal acquisition to optimize imaging of fluorescence resonance energy transfer by sensitized emission. Biophysical J 86: 2517-2529.
40. Verzijl D, Storelli S, Scholten DJ, Bosch L, Reinhart TA, Streblow DN, et al. (2008). Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J Pharmacol Exp Ther 325: 544-555.
41. Wilson S, Wilkinson G, Milligan G, (2005). The CXCR1and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. J Biol Chem 280: 28663-28674.
42. Zuurman MW, Heeroma J, Brouwer N, Boddeke HW, Biber K, (2003). LPS-induced expression of a novel chemokine receptor (L-CCR) in mouse glial cells in vitro and in vivo. Glia 41: 327-336.